- Home
- average bra size for 16 year olds
- CD24+/CD38- as new prognostic marker for non-small cell lung cancer, Multidisciplinary Respiratory Medicine
CD24+/CD38- as new prognostic marker for non-small cell lung cancer, Multidisciplinary Respiratory Medicine
5 (280) · $ 17.00 · In stock
Background Lung cancer is the leading cause of death among cancers in the world. The annual death toll due to this disease exceeds the combined deaths caused by colon, breast, prostate, and pancreatic cancers. As a result, there has been a tremendous effort to identify new biomarkers for early detection and diagnosis of lung cancer. Methods In this study we report the results of screening a panel of eight non-small cell lung cancer (NSCLC) cell lines originating from different subtypes of lung cancer in an attempt to identify potential biomarkers unique to this disease. We used real-time polymerase chain reaction and flow cytometry techniques to analyze the expression of ALDHA1, EpCAM, CD133, CD24, and CD38 in this panel. Results We demonstrate for the first time that the majority of NSCLC cells do not express levels of CD38 that would qualify it as a new biomarker for the disease. In contrast, we found that CD24 is over-expressed in 6 out of 8 of the cell lines. The combined CD24+/CD38-/low phenotype was detected in 50% of the cell lines that are also positive for CD133 and EpCAM. Conclusions We report that CD24+/CD38-/low signature could potentially be used as a new biomarker for the early detection of NSCLC.
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial, BMC Cancer
Imaging of Precision Therapy for Lung Cancer: Current State of the Art
Frontiers The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC), BMC Cancer
New advances in treating non-small cell lung cancer
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients
Cancers, Free Full-Text
WO2016154623A2 - Anti-cd133 monoclonal antibodies and related compositions and methods - Google Patents
Frontiers Role of CD38 in anti-tumor immunity of small cell lung cancer
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients
Clinical Case Scenarios: Approaches to Treatment Decisions in Non-Small Cell Lung Cancer
Frontiers Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity
